BT1769
BT1769 is a MT1-MMP-targeted (KD = 3.35 nM) Bicycle toxin conjugate. BT1769 can be used in the study for osteosarcoma. BT1769 consists of a novel bicyclic targeting peptide that selectively binds MT1-MMP; a cytotoxin MMAE; and an enzymatically cleavable dipeptide linker[1].
Product Specifications
UNSPSC
12352209
Target
MMP; Peptide-Drug Conjugates (PDCs)
Type
Peptides
Related Pathways
Antibody-drug Conjugate/ADC Related; Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bt1769.html
Smiles
[H][C@](CSCC1=CC(CN(C)C[C@H](NC([C@H](C)NC(CN(C)C(CN(C)C(CN(C)C(CN(C)C(CN(C)C(CN(C)C(CN(C)C(CN(C)C(CN(C)C(CN(C)C(CCNC(CCC2=CN(N=N2)CC(N[C@H](C(N[C@H](C(NC3=CC=C(COC(N([C@H](C(N[C@H](C(N([C@H]([C@H](OC)CC(N4[C@H]([C@H](OC)[C@H](C(N[C@@H]([C@H](C5=CC=CC=C5)O)C)=O)C)CCC4)=O)[C@H](CC)C)C)=O)C(C)C)=O)C(C)C)C)=O)C=C3)=O)CCCNC(N)=O)=O)C(C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)C(N[C@H](C)C(N[C@@H](CC(N)=O)C(N[C@@H](CCC(O)=O)C(N[C@H]6CC7=CC=CC8=C7C=CC=C8)=O)=O)=O)=O)=CC9=C1)(C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CN(C9)C)C(N)=O)=O)C(C)(C)C)=O)CC(O)=O)=O)CC%10=CC=C(C=C%10)O)=O)CC%11=CC=CC=C%11)=O)CC(O)=O)=O)CCC(O)=O)=O)NC([C@H](NC6=O)C)=O
Molecular Formula
C186H269N43O50S
Molecular Weight
3939.45
References & Citations
[1]Yifei Wang, et al. Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma. Mol Cancer Ther. 2022 Jun 1;21 (6) :903-913.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog